A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed Pfizer logo in this illustration taken, October 30, 2020. REUTERS/Dado RuvicBERLIN, Oct 21 (Reuters) - Pfizer Inc (PFE.N) and German partner BioNTech SE (22UAy.DE) on Thursday said data from a Phase III trial demonstrated…
Pfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant.
They said a trial of 10,000 participants aged 16 or older showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent.
The study also found that the booster shot had a favorable safety profile.
Discover more from News Facts Network
Subscribe to get the latest posts sent to your email.
